HCPLive

MR-US Fusion Targeted Biopsy Ups Detection of Prostate Cancer

 
THURSDAY, Dec. 13 (HealthDay News) -- Targeted biopsy of suspected prostate cancer lesions, identified using magnetic resonance-ultrasound (MR-US) fusion, increases prostate cancer detection and detects aggressive tumors that may be missed by conventional biopsy, according to a study published in the January issue of The Journal of Urology.

Geoffrey A. Sonn, M.D., from the University of California Los Angeles, and colleagues used MR-US fusion prostate biopsy in 171 men (median age, 65 years) undergoing biopsy as part of active surveillance (106 men) or due to increased prostate-specific antigen levels with a prior negative conventional biopsy (65 men). MR-US fusion prostate biopsy locates lesions by magnetic resonance imaging (MRI) and fuses it with real-time ultrasound to generate a three-dimensional prostate model to allow targeted sampling. The men also had conventional systematic biopsies taken.

The researchers identified prostate cancer in 53 percent of men, of whom 38 percent had cancer with Gleason grade 7 or greater. Of these highly-aggressive cancers, 38 percent were detected only by targeted biopsy. Of the 16 men with the highest level of suspicion by MRI (image grade 5 target), 94 percent had prostate cancer.

"Prostate lesions identified on MRI can be accurately targeted with MR-US fusion biopsy in a clinic setting using local anesthesia," Sonn and colleagues conclude. "Targeted prostate biopsy has the potential to improve the diagnosis of prostate cancer and may aid in the selection of patients for active surveillance and focal therapy."
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

An experimental vaccine and a drug already on the market each may help slow down advanced ovarian cancer, two new studies suggest. The findings were to be presented Saturday at the annual meeting of the Society of Gynecologic Oncology (SGO), held from March 28 to 31 in Chicago.

The ARTEMIS device provides a new perspective for urologists and patients alike when looking at potential prostate cancer patients.
Using the ARTEMIS device may take a little longer than the traditional MRI for prostate cancer, but with more rapid results and easier to read monitors for the patients and doctors, the results show real benefit in overall diagnosis.
For many years traditional ultrasound has been the main method of diagnosing prostate cancer. In recent years new developments in technology have provided a more effective and efficient method that can provide nearly instantaneous results.
$vAR$